<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176708</url>
  </required_header>
  <id_info>
    <org_study_id>Transplant isoglycemia (AP)</org_study_id>
    <nct_id>NCT01176708</nct_id>
  </id_info>
  <brief_title>Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion</brief_title>
  <official_title>The Significance of Intact Liver Innervation for the Glucose and GLP-1 Induced Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the significance of intact nerve supply to the liver
      for the glucagon-like peptide-1 (GLP-1) induced insulin secretion.

      The hypothesis is that the effects of GLP-1 is transmitted through the GLP-1 receptor and
      that these effects involve sensory afferent neurons, probably primarily parasympathetic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl
      peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis
      that GLP-1 interact locally with afferent sensory nerve fibers.

      The aim of this study is to investigate the significance of intact liver innervation for the
      GLP-1 induced insulin secretion in liver transplanted patients; kidney transplanted control
      patients matched for immunosuppressive treatment, age, gender and body weight; and ten
      control persons matched for age, gender and body weight.

      The insulin secretion will be evaluated from blood samples that will be analyzed for insulin
      and c-peptide.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>four hours</time_frame>
    <description>The insulin secretion during a four-hour oral glucose tolerance test (OGTT) and an intravenous isoglycaemic clamp is evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>20 time points within four hours</time_frame>
    <description>20 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GLP-1</measure>
    <time_frame>12 time points within four hours</time_frame>
    <description>12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GIP</measure>
    <time_frame>12 time points within four hours</time_frame>
    <description>12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma glucagon</measure>
    <time_frame>12 time points within four hours</time_frame>
    <description>12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GLP-2</measure>
    <time_frame>12 time points within four hours</time_frame>
    <description>12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma PYY</measure>
    <time_frame>12 time points within four hours</time_frame>
    <description>12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Liver transplanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Liver transplanted patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney transplanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 kidney transplanted individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipeptidyl peptidase 4 (DPP4) inhibitor</intervention_name>
    <description>One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3</description>
    <arm_group_label>Liver transplanted</arm_group_label>
    <arm_group_label>Kidney transplanted</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral glucose</intervention_name>
    <description>50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol</description>
    <arm_group_label>Liver transplanted</arm_group_label>
    <arm_group_label>Kidney transplanted</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Panodil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intravenous glucose</intervention_name>
    <description>1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test</description>
    <arm_group_label>Liver transplanted</arm_group_label>
    <arm_group_label>Kidney transplanted</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Panodil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal fasting plasma glucose

          -  normal hemoglobin

          -  informed consent

        Exclusion Criteria:

          -  type 1 diabetes mellitus or type 2 diabetes mellitus

          -  body mass index &gt; 30

          -  inflammatory bowel disease

          -  intestinal surgery

          -  serum creatinine &gt; 250 µM and/or albuminuria

          -  ALAT &gt; 2 x normal value

          -  Severe cardiac insufficiency

          -  in treatment with medicine which cannot be paused for 12 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Astrid Plamboeck, M.D.</last_name>
    <phone>+45 26208174</phone>
    <email>astridp@sund.ku.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine F' laboratory</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Plamboeck, M.D.</last_name>
      <phone>+45 26208174</phone>
      <email>astridp@sund.ku.dk</email>
    </contact>
    <contact_backup>
      <last_name>Tina Vilsbøll, M.D.</last_name>
      <phone>+45 39772461</phone>
      <email>tivi@geh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Astrid Plamboeck, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>January 5, 2012</last_update_submitted>
  <last_update_submitted_qc>January 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Jonatan I Bagger</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>kidney transplanted</keyword>
  <keyword>glucagon-like peptide-1</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>vagotomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

